Join Dr. Philip Baer June 20, 8pm ET for webinar featuring a virtual review of “Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab” (Tweehuysen et al, Arthritis Rheumatol, Jan 2018).

Please join Dr. Philip Baer for WEBINAR 2 of 2018 to be held Wednesday, June 20 at 8pm EST, focused on the recent article in Arthritis & Rheumatology by Tweehuysen et al:

Link to full text article:  Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab

For webinar access details, see calendar invitation, or email sent to you on June 5.

If you have any comments or questions, please contact:

Paul Abbass
LEGITIMED INC.
paul.abbass@legitimed.com